Bulgaria · Delayed Price · Currency is BGN · Price in EUR Sopharma AD Statistics
Total Valuation
Sopharma AD has a market cap or net worth of BGN 2.68 billion. The enterprise value is 3.22 billion.
| Market Cap | 2.68B |
| Enterprise Value | 3.22B |
Important Dates
The last earnings date was Monday, August 31, 2026.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | Jul 9, 2026 |
Share Statistics
Sopharma AD has 538.41 million shares outstanding. The number of shares has decreased by -25.97% in one year.
| Current Share Class | 538.41M |
| Shares Outstanding | 538.41M |
| Shares Change (YoY) | -25.97% |
| Shares Change (QoQ) | +1.05% |
| Owned by Insiders (%) | 9.82% |
| Owned by Institutions (%) | 0.28% |
| Float | 178.39M |
Valuation Ratios
The trailing PE ratio is 11.34.
| PE Ratio | 11.34 |
| Forward PE | n/a |
| PS Ratio | 0.97 |
| PB Ratio | 2.55 |
| P/TBV Ratio | 3.46 |
| P/FCF Ratio | 39.42 |
| P/OCF Ratio | 23.18 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.69, with an EV/FCF ratio of 47.35.
| EV / Earnings | 19.93 |
| EV / Sales | 1.15 |
| EV / EBITDA | 11.69 |
| EV / EBIT | 16.45 |
| EV / FCF | 47.35 |
Financial Position
The company has a current ratio of 1.43, with a Debt / Equity ratio of 0.52.
| Current Ratio | 1.43 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | 2.30 |
| Debt / FCF | 8.00 |
| Interest Coverage | 7.28 |
Financial Efficiency
Return on equity (ROE) is 17.20% and return on invested capital (ROIC) is 9.27%.
| Return on Equity (ROE) | 17.20% |
| Return on Assets (ROA) | 4.98% |
| Return on Invested Capital (ROIC) | 9.27% |
| Return on Capital Employed (ROCE) | 12.23% |
| Weighted Average Cost of Capital (WACC) | 4.63% |
| Revenue Per Employee | 456,965 |
| Profits Per Employee | 26,743 |
| Employee Count | 6,049 |
| Asset Turnover | 1.39 |
| Inventory Turnover | 4.39 |
Taxes
In the past 12 months, Sopharma AD has paid 17.31 million in taxes.
| Income Tax | 17.31M |
| Effective Tax Rate | 9.34% |
Stock Price Statistics
The stock price has increased by +85.75% in the last 52 weeks. The beta is 0.11, so Sopharma AD's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | +85.75% |
| 50-Day Moving Average | 2.03 |
| 200-Day Moving Average | 1.82 |
| Relative Strength Index (RSI) | 87.51 |
| Average Volume (20 Days) | 101,711 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sopharma AD had revenue of BGN 2.76 billion and earned 161.77 million in profits. Earnings per share was 0.43.
| Revenue | 2.76B |
| Gross Profit | 680.63M |
| Operating Income | 158.61M |
| Pretax Income | 185.42M |
| Net Income | 161.77M |
| EBITDA | 219.40M |
| EBIT | 158.61M |
| Earnings Per Share (EPS) | 0.43 |
Balance Sheet
The company has 46.68 million in cash and 544.95 million in debt, with a net cash position of -498.28 million or -0.93 per share.
| Cash & Cash Equivalents | 46.68M |
| Total Debt | 544.95M |
| Net Cash | -498.28M |
| Net Cash Per Share | -0.93 |
| Equity (Book Value) | 1.05B |
| Book Value Per Share | 1.90 |
| Working Capital | 326.41M |
Cash Flow
In the last 12 months, operating cash flow was 115.79 million and capital expenditures -47.70 million, giving a free cash flow of 68.09 million.
| Operating Cash Flow | 115.79M |
| Capital Expenditures | -47.70M |
| Depreciation & Amortization | 62.52M |
| Net Borrowing | -98.45M |
| Free Cash Flow | 68.09M |
| FCF Per Share | 0.13 |
Margins
Gross margin is 24.62%, with operating and profit margins of 5.74% and 5.85%.
| Gross Margin | 24.62% |
| Operating Margin | 5.74% |
| Pretax Margin | 6.71% |
| Profit Margin | 5.85% |
| EBITDA Margin | 7.94% |
| EBIT Margin | 5.74% |
| FCF Margin | 2.39% |
Dividends & Yields
This stock pays an annual dividend of 0.14, which amounts to a dividend yield of 3.05%.
| Dividend Per Share | 0.14 |
| Dividend Yield | 3.05% |
| Dividend Growth (YoY) | 80.70% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 35.71% |
| Buyback Yield | 25.97% |
| Shareholder Yield | 29.02% |
| Earnings Yield | 6.03% |
| FCF Yield | 2.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 10, 2025. It was a forward split with a ratio of 3.
| Last Split Date | Jul 10, 2025 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Sopharma AD has an Altman Z-Score of 3.04 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.04 |
| Piotroski F-Score | 6 |